Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 60Carcinoma, Hepatocellular 43Colorectal Neoplasms 32Stomach Neoplasms 28Esophageal Squamous Cell Carcinoma 27Squamous Cell Carcinoma of Head and Neck 20Esophageal Neoplasms 14Small Cell Lung Carcinoma 13Neoplasm Metastasis 13Lung Neoplasms 13Head and Neck Neoplasms 12Advanced Solid Tumor 12Cholangiocarcinoma 11Triple Negative Breast Neoplasms 10Rectal Neoplasms 10Nasopharyngeal Carcinoma 10Melanoma 10Uterine Cervical Neoplasms 9Recurrence 9Neoplasms 9Colonic Neoplasms 9Pancreatic Neoplasms 7Urinary Bladder Neoplasms 6Solid Tumor 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Sarcoma 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma 5Hodgkin Disease 5

Interventions

tislelizumab 1Oxaliplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mid-low Rectal Cancer × tislelizumab × Clear all
NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Completed
38 enrolled
Gastrointestinal

Mid-low Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡